electroCore, Inc. (NASDAQ: ECOR) Stock Competitors & Peer Comparison

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ABT has a market cap of 176.2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ABT trades at $101.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ABT's P/E ratio is 19.55. In terms of profitability, ECOR's ROE is +5.25%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ABT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ECOR's ROE is +5.25%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BSX-PA's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, MDT has a market cap of 117.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while MDT trades at $91.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas MDT's P/E ratio is 16.61. In terms of profitability, ECOR's ROE is +5.25%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check MDT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SYK has a market cap of 108.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SYK trades at $282.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SYK's P/E ratio is 21.11. In terms of profitability, ECOR's ROE is +5.25%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ECOR is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SYK's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BSX has a market cap of 65.2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BSX trades at $43.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BSX's P/E ratio is 14.15. In terms of profitability, ECOR's ROE is +5.25%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BSX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, EW has a market cap of 49.7B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while EW trades at $86.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas EW's P/E ratio is 32.00. In terms of profitability, ECOR's ROE is +5.25%, compared to EW's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check EW's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, DXCM has a market cap of 32.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while DXCM trades at $85.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas DXCM's P/E ratio is 33.69. In terms of profitability, ECOR's ROE is +5.25%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ECOR is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check DXCM's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, GEHC has a market cap of 30.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while GEHC trades at $67.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas GEHC's P/E ratio is 14.86. In terms of profitability, ECOR's ROE is +5.25%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check GEHC's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while PHG trades at $24.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas PHG's P/E ratio is 14.13. In terms of profitability, ECOR's ROE is +5.25%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PHG's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ZBH has a market cap of 17.8B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ZBH trades at $92.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ZBH's P/E ratio is 10.87. In terms of profitability, ECOR's ROE is +5.25%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ECOR is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ZBH's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ECOR's ROE is +5.25%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ABMD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while PEN trades at $320.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas PEN's P/E ratio is 83.80. In terms of profitability, ECOR's ROE is +5.25%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PEN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ECOR's ROE is +5.25%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ECOR is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SWAV's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SNN has a market cap of 11.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SNN trades at $27.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SNN's P/E ratio is 18.67. In terms of profitability, ECOR's ROE is +5.25%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ECOR is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SNN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BIO-B trades at $380.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BIO-B's P/E ratio is -66.99. In terms of profitability, ECOR's ROE is +5.25%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ECOR is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BIO-B's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while GMED trades at $76.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas GMED's P/E ratio is 17.17. In terms of profitability, ECOR's ROE is +5.25%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ECOR is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check GMED's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ALGN has a market cap of 10.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ALGN trades at $140.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ALGN's P/E ratio is 12.80. In terms of profitability, ECOR's ROE is +5.25%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ECOR is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ALGN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, GKOS has a market cap of 9.9B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while GKOS trades at $168.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas GKOS's P/E ratio is -195.40. In terms of profitability, ECOR's ROE is +5.25%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ECOR is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check GKOS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BIO has a market cap of 9.8B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BIO trades at $364.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BIO's P/E ratio is 39.31. In terms of profitability, ECOR's ROE is +5.25%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ECOR is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BIO's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, PODD has a market cap of 9.7B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while PODD trades at $139.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas PODD's P/E ratio is 23.82. In terms of profitability, ECOR's ROE is +5.25%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ECOR is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PODD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas MASI's P/E ratio is 44.43. In terms of profitability, ECOR's ROE is +5.25%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ECOR is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check MASI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BRKR trades at $56.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BRKR's P/E ratio is 28.27. In terms of profitability, ECOR's ROE is +5.25%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ECOR is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BRKR's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BRKRP has a market cap of 8.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BRKRP trades at $415.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BRKRP's P/E ratio is 226.58. In terms of profitability, ECOR's ROE is +5.25%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ECOR is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BRKRP's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, HAE has a market cap of 5.5B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while HAE trades at $122.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas HAE's P/E ratio is 24.36. In terms of profitability, ECOR's ROE is +5.25%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check HAE's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas NARI's P/E ratio is -59.24. In terms of profitability, ECOR's ROE is +5.25%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ECOR is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NARI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ITGR trades at $126.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ITGR's P/E ratio is 19.93. In terms of profitability, ECOR's ROE is +5.25%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ECOR is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ITGR's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while LIVN trades at $77.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas LIVN's P/E ratio is 18.35. In terms of profitability, ECOR's ROE is +5.25%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check LIVN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ECOR's ROE is +5.25%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AXNX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while IRTC trades at $106.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas IRTC's P/E ratio is -248.09. In terms of profitability, ECOR's ROE is +5.25%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ECOR is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check IRTC's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, TMDX has a market cap of 2.7B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while TMDX trades at $78.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas TMDX's P/E ratio is 39.68. In terms of profitability, ECOR's ROE is +5.25%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ECOR is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TMDX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while NEOG trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas NEOG's P/E ratio is 42.86. In terms of profitability, ECOR's ROE is +5.25%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, ECOR is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NEOG's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while UFPT trades at $295.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas UFPT's P/E ratio is 30.22. In terms of profitability, ECOR's ROE is +5.25%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ECOR is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check UFPT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BFLY trades at $8.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BFLY's P/E ratio is -35.65. In terms of profitability, ECOR's ROE is +5.25%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ECOR is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BFLY's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ECOR's ROE is +5.25%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ECOR is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NUVA's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while INSP trades at $71.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas INSP's P/E ratio is 31.49. In terms of profitability, ECOR's ROE is +5.25%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ECOR is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check INSP's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, AXGN has a market cap of 2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while AXGN trades at $37.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas AXGN's P/E ratio is 97.66. In terms of profitability, ECOR's ROE is +5.25%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ECOR is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AXGN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ESTA trades at $61.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ESTA's P/E ratio is -48.91. In terms of profitability, ECOR's ROE is +5.25%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ECOR is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ESTA's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ATEC trades at $11.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ATEC's P/E ratio is -187.50. In terms of profitability, ECOR's ROE is +5.25%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ECOR is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ATEC's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while NVCR trades at $14.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas NVCR's P/E ratio is -11.32. In terms of profitability, ECOR's ROE is +5.25%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ECOR is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NVCR's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CNMD trades at $45.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CNMD's P/E ratio is 9.92. In terms of profitability, ECOR's ROE is +5.25%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ECOR is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CNMD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ECOR's ROE is +5.25%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ECOR is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check HSKA's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ECOR's ROE is +5.25%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ECOR is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AVNS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while IRMD trades at $89.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas IRMD's P/E ratio is 44.96. In terms of profitability, ECOR's ROE is +5.25%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ECOR is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check IRMD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while TNDM trades at $16.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas TNDM's P/E ratio is -17.69. In terms of profitability, ECOR's ROE is +5.25%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ECOR is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TNDM's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SILK's P/E ratio is -18.96. In terms of profitability, ECOR's ROE is +5.25%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ECOR is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SILK's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while PRCT trades at $19.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas PRCT's P/E ratio is -10.09. In terms of profitability, ECOR's ROE is +5.25%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ECOR is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PRCT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas FNA's P/E ratio is -19.83. In terms of profitability, ECOR's ROE is +5.25%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ECOR is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check FNA's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while IART trades at $13.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas IART's P/E ratio is 5.92. In terms of profitability, ECOR's ROE is +5.25%, compared to IART's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check IART's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while AORT trades at $21.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas AORT's P/E ratio is 36.33. In terms of profitability, ECOR's ROE is +5.25%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ECOR is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AORT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ENOV trades at $18.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ENOV's P/E ratio is 5.23. In terms of profitability, ECOR's ROE is +5.25%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ECOR is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ENOV's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while LMRI trades at $10.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas LMRI's P/E ratio is -20.78. In terms of profitability, ECOR's ROE is +5.25%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ECOR is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check LMRI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CBLL has a market cap of 958.4M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CBLL trades at $25.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CBLL's P/E ratio is -14.35. In terms of profitability, ECOR's ROE is +5.25%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ECOR is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CBLL's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BVS has a market cap of 916.6M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BVS trades at $13.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BVS's P/E ratio is 17.80. In terms of profitability, ECOR's ROE is +5.25%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ECOR is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BVS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SIBN has a market cap of 891.4M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SIBN trades at $20.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SIBN's P/E ratio is -59.12. In terms of profitability, ECOR's ROE is +5.25%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ECOR is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SIBN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CSII's P/E ratio is -20.83. In terms of profitability, ECOR's ROE is +5.25%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ECOR is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CSII's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, AHCO has a market cap of 835.4M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while AHCO trades at $6.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas AHCO's P/E ratio is 12.53. In terms of profitability, ECOR's ROE is +5.25%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ECOR is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AHCO's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, INMD has a market cap of 822M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while INMD trades at $14.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas INMD's P/E ratio is 9.93. In terms of profitability, ECOR's ROE is +5.25%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ECOR is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check INMD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BBNX has a market cap of 803.5M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BBNX trades at $17.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BBNX's P/E ratio is -10.82. In terms of profitability, ECOR's ROE is +5.25%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ECOR is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check BBNX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, VREX has a market cap of 778M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while VREX trades at $18.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas VREX's P/E ratio is 19.45. In terms of profitability, ECOR's ROE is +5.25%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ECOR is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check VREX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CTKB has a market cap of 692.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CTKB trades at $5.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CTKB's P/E ratio is -28.40. In terms of profitability, ECOR's ROE is +5.25%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ECOR is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CTKB's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, PACB has a market cap of 652.3M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while PACB trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas PACB's P/E ratio is -5.12. In terms of profitability, ECOR's ROE is +5.25%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ECOR is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check PACB's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, AVR has a market cap of 646.6M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while AVR trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas AVR's P/E ratio is -3.43. In terms of profitability, ECOR's ROE is +5.25%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ECOR is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check AVR's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ECOR's ROE is +5.25%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ECOR is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SRDX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas APEN's P/E ratio is -9.43. In terms of profitability, ECOR's ROE is +5.25%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ECOR is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check APEN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, KIDS has a market cap of 567.1M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while KIDS trades at $22.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas KIDS's P/E ratio is -18.71. In terms of profitability, ECOR's ROE is +5.25%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ECOR is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check KIDS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ECOR's ROE is +5.25%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, ECOR is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ZIMV's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, DCTH has a market cap of 519.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while DCTH trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas DCTH's P/E ratio is 1504.00. In terms of profitability, ECOR's ROE is +5.25%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ECOR is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check DCTH's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SSII has a market cap of 510.3M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SSII trades at $2.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SSII's P/E ratio is -42.50. In terms of profitability, ECOR's ROE is +5.25%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ECOR is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SSII's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, TCMD has a market cap of 510.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while TCMD trades at $22.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas TCMD's P/E ratio is 20.94. In terms of profitability, ECOR's ROE is +5.25%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ECOR is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TCMD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SGHT has a market cap of 487.8M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SGHT trades at $8.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SGHT's P/E ratio is -16.01. In terms of profitability, ECOR's ROE is +5.25%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ECOR is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SGHT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CERS has a market cap of 455.4M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CERS trades at $2.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CERS's P/E ratio is -75.08. In terms of profitability, ECOR's ROE is +5.25%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ECOR is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CERS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, NPCE has a market cap of 443.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while NPCE trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas NPCE's P/E ratio is -22.81. In terms of profitability, ECOR's ROE is +5.25%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ECOR is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NPCE's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SENS has a market cap of 386.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SENS trades at $9.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SENS's P/E ratio is -4.14. In terms of profitability, ECOR's ROE is +5.25%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ECOR is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SENS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, OFIX has a market cap of 375.1M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while OFIX trades at $9.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas OFIX's P/E ratio is -6.04. In terms of profitability, ECOR's ROE is +5.25%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ECOR is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check OFIX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, RCEL has a market cap of 332.1M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while RCEL trades at $13.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas RCEL's P/E ratio is -9.28. In terms of profitability, ECOR's ROE is +5.25%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ECOR is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check RCEL's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CV has a market cap of 330.8M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CV trades at $6.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CV's P/E ratio is -10.51. In terms of profitability, ECOR's ROE is +5.25%, compared to CV's ROE of -1.78%. Regarding short-term risk, ECOR is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CV's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ECOR's ROE is +5.25%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, ECOR is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check SMLR's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CLPT has a market cap of 305.9M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CLPT trades at $10.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CLPT's P/E ratio is -8.64. In terms of profitability, ECOR's ROE is +5.25%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ECOR is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CLPT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, CATX has a market cap of 286.8M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while CATX trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas CATX's P/E ratio is -1.89. In terms of profitability, ECOR's ROE is +5.25%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ECOR is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check CATX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, INFU has a market cap of 275.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while INFU trades at $13.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas INFU's P/E ratio is 33.26. In terms of profitability, ECOR's ROE is +5.25%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ECOR is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check INFU's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, QSI has a market cap of 269M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while QSI trades at $1.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas QSI's P/E ratio is -2.96. In terms of profitability, ECOR's ROE is +5.25%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ECOR is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check QSI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, TMCI has a market cap of 266M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while TMCI trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas TMCI's P/E ratio is -4.36. In terms of profitability, ECOR's ROE is +5.25%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ECOR is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TMCI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, PROF has a market cap of 263.4M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while PROF trades at $7.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas PROF's P/E ratio is -7.40. In terms of profitability, ECOR's ROE is +5.25%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ECOR is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check PROF's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, TLSI has a market cap of 254.9M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while TLSI trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas TLSI's P/E ratio is -2.46. In terms of profitability, ECOR's ROE is +5.25%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ECOR is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check TLSI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ECOR's ROE is +5.25%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, ECOR is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check MGRM's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ELMD has a market cap of 232.5M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ELMD trades at $28.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ELMD's P/E ratio is 21.44. In terms of profitability, ECOR's ROE is +5.25%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ECOR is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ELMD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ECOR's ROE is +5.25%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ECOR is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check NVRO's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, RXST has a market cap of 192.9M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while RXST trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas RXST's P/E ratio is -4.12. In terms of profitability, ECOR's ROE is +5.25%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ECOR is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check RXST's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ECOR's ROE is +5.25%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, ECOR is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check BSGM's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ECOR's ROE is +5.25%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ECOR is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check MDGS's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, INGN has a market cap of 173.8M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while INGN trades at $6.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas INGN's P/E ratio is -7.05. In terms of profitability, ECOR's ROE is +5.25%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ECOR is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check INGN's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ECOR's ROE is +5.25%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, ECOR is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check QIPT's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, FOCL has a market cap of 161.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while FOCL trades at $4.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas FOCL's P/E ratio is -4.16. In terms of profitability, ECOR's ROE is +5.25%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ECOR is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check FOCL's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, QTRX has a market cap of 148.9M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while QTRX trades at $3.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas QTRX's P/E ratio is -1.24. In terms of profitability, ECOR's ROE is +5.25%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ECOR is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check QTRX's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, STIM has a market cap of 148.2M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while STIM trades at $2.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas STIM's P/E ratio is -4.84. In terms of profitability, ECOR's ROE is +5.25%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ECOR is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check STIM's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, LUCD has a market cap of 114M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while LUCD trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas LUCD's P/E ratio is -1.61. In terms of profitability, ECOR's ROE is +5.25%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ECOR is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ECOR.Check LUCD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ECOR's ROE is +5.25%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ECOR is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ICAD's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas HJLI's P/E ratio is N/A. In terms of profitability, ECOR's ROE is +5.25%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ECOR is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check HJLI's competition here

electroCore, Inc. (NASDAQ: ECOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ECOR stands at 83.7M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ECOR is priced at $9.28 on the NASDAQ, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ECOR currently has a P/E ratio of -5.52, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ECOR's ROE is +5.25%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ECOR is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ECOR.Check ASXC's competition here